MSB Overzicht aandelen Mesoblast Limited houdt zich bezig met de ontwikkeling van regeneratieve geneesmiddelen in Australië, de Verenigde Staten, Singapore en Zwitserland. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
Mesoblast Limited Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Mesoblast Historische aandelenkoersen Huidige aandelenkoers AU$3.34 52 Week Hoogtepunt AU$3.37 52 Week Laag AU$0.26 Bèta 2.31 1 maand verandering 80.05% 3 maanden verandering 122.67% 1 Jaar Verandering 1,041.88% 3 jaar verandering 153.99% 5 jaar verandering 44.59% Verandering sinds IPO -29.76%
Recent nieuws en updates
Forecast breakeven date moved forward to 2026 Dec 31 Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 1.511944 million. Dec 21
Mesoblast Limited’s RYONCIL® is the First U.S. FDA-Approves Mesenchymal Stromal Cell (MSC) Therapy Dec 19
FDA Grants Revascor (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease Dec 05
Mesoblast Limited Announces Publication in the November 2024 Online Issue of the European Journal of Heart Failure Dec 03
Mesoblast Limited, Annual General Meeting, Nov 15, 2024 Oct 17 Meer updates bekijken
Forecast breakeven date moved forward to 2026 Dec 31 Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 1.511944 million. Dec 21
Mesoblast Limited’s RYONCIL® is the First U.S. FDA-Approves Mesenchymal Stromal Cell (MSC) Therapy Dec 19
FDA Grants Revascor (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease Dec 05
Mesoblast Limited Announces Publication in the November 2024 Online Issue of the European Journal of Heart Failure Dec 03
Mesoblast Limited, Annual General Meeting, Nov 15, 2024 Oct 17
Forecast breakeven date pushed back to 2027 Aug 30
Full year 2024 earnings released: US$0.089 loss per share (vs US$0.11 loss in FY 2023) Aug 29
Mesoblast Limited Announces the United States Food and Drug Administration Has Accepted Its Biologics License Application (Bla) Resubmission for Ryoncil® Jul 24
Mesoblast Limited Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain Jul 22
Mesoblast Limited Resources Biologics Licence Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in the Treatment of Children with SR-aGVHD Jul 10
Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week Jul 01
Independent Non-Executive Director recently bought AU$200k worth of stock Apr 17
No longer forecast to breakeven Apr 05
United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease Mar 27
New minor risk - Share price stability Mar 26 Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.93 million. Mar 23
New major risk - Shareholder dilution Mar 18 Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 97.041224 million. Mar 14
Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device Mar 11
No longer forecast to breakeven Mar 01
First half 2024 earnings released: US$0.038 loss per share (vs US$0.057 loss in 1H 2023) Feb 29
United States Food & Drug Administration Grants Mesoblast Rare Pediatric Disease Designation for Revascor®? (Rexlemestrocel-L) in Children with Congenital Heart Disease Jan 19
Mesoblast Limited, Annual General Meeting, Nov 28, 2023 Oct 30
Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee Sep 27
Mesoblast Limited Provides an Update on the Path to Approval for Its Lead-Product Candidate Remestemcel-L in the Treatment of Pediatric and Adult Steroid-Refractory Acute Graft Versus Host Disease Sep 22
Full year 2023 earnings released: US$0.11 loss per share (vs US$0.14 loss in FY 2022) Aug 31
New major risk - Share price stability Aug 05
Forecast breakeven date pushed back to 2026 Aug 05
Mesoblast Limited Receives Complete Response from U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children Aug 04
Mesoblast Limited Appoints Dr. Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role Jun 05
Third quarter 2023 earnings released: US$0.025 loss per share (vs US$0.033 loss in 3Q 2022) May 26
No longer forecast to breakeven Mar 11
Second quarter 2023 earnings released: US$0.033 loss per share (vs US$0.04 loss in 2Q 2022) Feb 28
Remestemcel-L Clinical and Potency Studies Presented At Premier Meeting of Transplantation Research and Therapy Feb 17
Mesoblast Limited Announces FDA Grants Regenerative Medicine Advanced Therapy Designation for Rexlemestrocel-L in Chronic Low Back Pain Feb 09 Mesoblast Limited Resubmits Biologic License Application to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD) Feb 01
First quarter 2023 earnings released: US$0.024 loss per share (vs US$0.035 loss in 1Q 2022) Nov 24
Mesoblast Limited Announces Top-Line Long-Term Survival Results for Remestemcel-L from its Pivotal Phase 3 Trial (GVHD-001) in Children with Steroid-Refractory Acute Graft-Versus-Host Disease Nov 23
Mesoblast Limited, Annual General Meeting, Nov 23, 2022 Oct 25
Mesoblast Limited Submits New Information to FDA File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD Oct 04
Insider recently bought AU$111k worth of stock Sep 13
Full year 2022 earnings released: US$0.14 loss per share (vs US$0.16 loss in FY 2021) Sep 01
Mesoblast Limited Announces Board Changes Aug 18
Mesoblast Limited Announces Single Intervention with Rexlemestrocel-L Improves Left Ventricular Ejection Fraction At 12 Months, Preceding Long-Term Reduction in Major Adverse Cardiovascular Events Jul 19
Forecast to breakeven in 2025 Jul 01
Mesoblast Limited Provides Litigation Update Jun 18
Third quarter 2022 earnings released: US$0.033 loss per share (vs US$0.044 loss in 3Q 2021) Jun 02
Mesoblast Limited Provides Update on Survival Outcomes in Covid-19 ARDS Patients Treated with Remestemcel-L May 31
Mesoblast Limited Announces Class Action Proceeding in the Federal Court of Australia May 24
Mesoblast Limited Announces Executive Changes Apr 07
Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint Feb 27
Donal O'Dwyer Retires from the Board of Mesoblast Limited Feb 25
Mesoblast Limited Announces Positive Results from an Interim Analysis of the First Patient Cohort in the Randomized, Controlled Study of Remestemcel-L by Direct Endoscopic Delivery to Areas of Inflammation in Patients with Medically Refractory Ulcerative Colitis or Crohn's Colitis Feb 22
Mesoblast Limited Appoints Eric Rose as Chief Medical Officer Feb 02
Forecast to breakeven in 2024 Jan 28
Mesoblast Limited Announces 36-Month Results of Phase 3 Trial in Chronic Low Back Pain Jan 12
Mesoblast Provides Update Following Meeting with FDA’s OTAT on Remestemcel-L for Children with Acute Graft Versus Host Disease Jan 01
No longer forecast to breakeven Jan 01
Mesoblast Limited Receives Feedback from the US Food & Drug Administration’S Office of Tissues and Advanced Therapies on the Phase 3 Program of Rexlemestrocel-L Dec 17
Insufficient new directors Dec 06
First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Nov 25
Mesoblast Limited announced that it expects to receive $90 million in funding from Oaktree Capital Management, L.P. Nov 23
Forecast to breakeven in 2024 Sep 23
Full year 2021 earnings released: US$0.15 loss per share (vs US$0.15 loss in FY 2020) Sep 02
Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference Jul 16
Mesoblast Limited Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease Jul 02
Forecast to breakeven in 2024 Jun 30
Third quarter 2021 earnings released: US$0.044 loss per share (vs US$0.028 loss in 3Q 2020) Jun 04
Forecast to breakeven in 2024 Jun 04
Mesoblast Limited Improves Outcomes in Inflammatory Lung Disease with Remestemcel-L Published in Respiratory Research Journal May 25
Mesoblast Limited Announces the 60 Day Results from the Randomized Controlled Trial of remestemcel-L in 222 Ventilator-Dependent COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Which Had Been Halted After the Third Interim Analysis May 02
Mesoblast Limited announced that it expects to receive AUD 138.251367 million in funding Mar 04
Revenue beats expectations Feb 28
Second quarter 2021 earnings released: US$0.044 loss per share (vs US$0.046 loss in 2Q 2020) Feb 27
Mesoblast Limited Announces Positive Outcomes of First Children Treated with Remestemcel-L for Multisystem Inflammatory Syndrome (MIS-C) and Heart Failure Post-Covid-19 Published in Pediatrics Feb 20
Mesoblast Limited Announces Results from the Phase 3 Randomized Controlled Trial of Its Allogeneic Mesenchymal Precursor Cell Therapy Feb 11
Mesoblast Limited Presents Heart Failure Phase 3 Trial Results At Investor Healthcare Conference Jan 20
Mesoblast Limited Announces Additional Results from the Landmark Dream-Hf Randomized Controlled Phase 3 Trial in 537 Treated Patients with Chronic Heart Failure with Reduced Left Ventricular Ejection Fraction (HFrEF) Who Received Rexlemestrocel-L (REVASCOR) or Control Sham Jan 12
Mesoblast Limited Announces Update on Covid-19 ARDS Trial Dec 19
New 90-day low: AU$2.43 Dec 18
Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure Dec 15
Mesoblast Limited Announces United States Food and Drug Administration Granted Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to Covid-19 Infection Dec 09
Mesoblast Limited Announces FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to COVID-19 Dec 03
Mesoblast Limited announced that it expects to receive $25 million in funding from Novartis AG Nov 21
First quarter 2021 earnings released: US$0.042 loss per share Nov 21
Revenue misses expectations Nov 21
Mesoblast Limited Enters into an Exclusive Worldwide License and Collaboration Agreement with Novartis for the Development, Manufacture and Commercialization of Remestemcel-L Nov 20
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been File Against Precigen, Royal Caribbean, Mesoblast and Loop Industries Nov 19 The Law Offices of Frank R. Cruz Announces Class Action Lawsuit Against Mesoblast Limited
Rosen Law Firm Reminds Mesoblast Limited Investors of Important Deadline Nov 05
New 90-day low: AU$3.06 Oct 28 Rendement voor aandeelhouders MSB AU Biotechs AU Markt 7D 30.0% 0.6% -0.6% 1Y 1,041.9% 4.2% 7.4%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: MSB overtrof de Australian Biotechs industrie, die het afgelopen jaar een rendement 4.2 % opleverde.
Rendement versus markt: MSB overtrof de Australian markt, die het afgelopen jaar een rendement opleverde van 7.4 %.
Prijsvolatiliteit Is MSB's price volatile compared to industry and market? MSB volatility MSB Average Weekly Movement 19.3% Biotechs Industry Average Movement 9.9% Market Average Movement 8.0% 10% most volatile stocks in AU Market 16.8% 10% least volatile stocks in AU Market 3.0%
Stabiele aandelenkoers: De aandelenkoers van MSB is de afgelopen 3 maanden volatiel geweest.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 19% ) van MSB is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Australian.
Over het bedrijf Mesoblast Limited houdt zich bezig met de ontwikkeling van regeneratieve geneeskundeproducten in Australië, de Verenigde Staten, Singapore en Zwitserland. Het gepatenteerde technologieplatform voor regeneratieve geneeskunde is gebaseerd op gespecialiseerde cellen die bekend staan als mesenchymale cellen. Het bedrijf biedt Remestemcel-L aan, dat zich in Fase III van het klinisch onderzoek bevindt voor de behandeling van systemische ontstekingsziekten, waaronder steroïde refractaire acute graft versus host ziekte en biologische refractaire inflammatoire darmziekte, evenals de ziekte van Crohn; en Remestemcel-L, dat zich in Fase III van het klinisch onderzoek bevindt voor de behandeling van chronisch hartfalen en chronische lage rugpijn als gevolg van degeneratieve discusziekte.
Meer tonen Mesoblast Limited Samenvatting Hoe verhouden de winst en inkomsten van Mesoblast zich tot de beurswaarde? MSB fundamentele statistieken Marktkapitalisatie AU$3.82b Inkomsten(TTM ) -AU$141.50m Inkomsten(TTM ) AU$9.50m
402.6x P/S-verhouding
-27.0x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) MSB resultatenrekening (TTM ) Inkomsten US$5.90m Kosten van inkomsten US$41.07m Brutowinst -US$35.17m Overige uitgaven US$52.79m Inkomsten -US$87.96m
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) -0.077 Brutomarge -595.87% Nettowinstmarge -1,490.27% Schuld/Eigen Vermogen Verhouding 23.8%
Hoe presteerde MSB op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2025/01/02 03:35 Aandelenkoers aan het einde van de dag 2025/01/02 00:00 Inkomsten 2024/06/30 Jaarlijkse inkomsten 2024/06/30
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten Mesoblast Limited wordt gevolgd door 24 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Dennis Hulme APP Securities Pty Ltd. Russell Wright Barclay Pearce Capital Pty Limited John Hester Bell Potter
Toon 21 meer analisten 
